184 related articles for article (PubMed ID: 38297256)
1. Is switching intravesical chemotherapeutic agents beneficial in short-term recurrent high-risk non-muscle-invasive bladder tumors? A 5-year retrospective study.
Chen S; Sun G; Chen X; Salgado T; Wu S; Hu H; Liu R; Qie Y
BMC Urol; 2024 Jan; 24(1):25. PubMed ID: 38297256
[TBL] [Abstract][Full Text] [Related]
2. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
3. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Cao M; Ma CK; Ma J; Chen HG; Xue W
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):385-7. PubMed ID: 21875472
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
Chevuru PT; McElree IM; Mott SL; Steinberg RL; O'Donnell MA; Packiam VT
Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
[TBL] [Abstract][Full Text] [Related]
6. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
7. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
[TBL] [Abstract][Full Text] [Related]
8. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
[TBL] [Abstract][Full Text] [Related]
10. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
11. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.
Böhle A; Leyh H; Frei C; Kühn M; Tschada R; Pottek T; Wagner W; Knispel HH; von Pokrzywnitzki W; Zorlu F; Helsberg K; Lübben B; Soldatenkova V; Stoffregen C; Büttner H;
Eur Urol; 2009 Sep; 56(3):495-503. PubMed ID: 19560257
[TBL] [Abstract][Full Text] [Related]
12. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
[TBL] [Abstract][Full Text] [Related]
13. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Messing EM; Tangen CM; Lerner SP; Sahasrabudhe DM; Koppie TM; Wood DP; Mack PC; Svatek RS; Evans CP; Hafez KS; Culkin DJ; Brand TC; Karsh LI; Holzbeierlein JM; Wilson SS; Wu G; Plets M; Vogelzang NJ; Thompson IM
JAMA; 2018 May; 319(18):1880-1888. PubMed ID: 29801011
[TBL] [Abstract][Full Text] [Related]
14. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
15. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
Xu S; Tan S; Wu T; Gu J; Xu L; Che X
Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
[TBL] [Abstract][Full Text] [Related]
17. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
Lone Z; Benidir T; Wood A; Campbell RA; Alaghehbandan R; Li J; Haber GP; Eltemamy M; Haywood SC; Weight CJ; Lee BH; Almassi N
Urol Oncol; 2024 Mar; 42(3):71.e1-71.e7. PubMed ID: 38135626
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596
[TBL] [Abstract][Full Text] [Related]
19. The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
Chen JX; Huang WT; Zhang QY; Deng CE; Wei JL; Xie YL; Lin R; Feng GZ; Yang GL; Long J; Lu HY; Mo ZN
BMC Cancer; 2023 Oct; 23(1):1018. PubMed ID: 37872516
[TBL] [Abstract][Full Text] [Related]
20. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis.
Corsi NJ; Messing EM; Sood A; Keeley J; Bronkema C; Rakic N; Jamil M; Dalela D; Arora S; Piontkowski AJ; Majdalany SE; Butaney M; Rakic I; Li P; Menon M; Rogers CG; Abdollah F
Clin Genitourin Cancer; 2022 Dec; 20(6):e498-e505. PubMed ID: 35871040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
